IGHE and Increased total eosinophil count: The following additional data were used to requalify patients: blood eosinophilia (n = 63; 100.00% of requalifications), comorbidities (n = 30; 47.62%) of which dupilumab qualifications constituted n = 13 (65%), and total IgE serum level (n = 8; 12.70%), tested in two (100.00%) omalizumab qualification cases (Table S3).